Gilead's $1,000-a-pill hepatitis C drug breaks records, drives Q2 profit
July 23, 2014 at 16:15 PM EDT
With record-breaking revenue from its controversial hepatitis C drug, Gilead Sciences Inc. scored a second-quarter profit of nearly $3...